GSK plc announced on March 3, 2025, that the US FDA has accepted for review the application for its drug depemokimab for asthma and chronic rhinosinusitis, with a decision expected by December 16, 2025.
AI Assistant
GSK PLC
2025
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.